Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab—a review
- 1 April 2019
- journal article
- review article
- Published by Elsevier BV in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 127 (4), 289-299
- https://doi.org/10.1016/j.oooo.2018.11.012
Abstract
No abstract availableKeywords
This publication has 75 references indexed in Scilit:
- Osteonecrosis of the jaw in a Crohn’s disease patient following a course of Bisphosphonate and Adalimumab therapy: a case reportBMC Gastroenterology, 2014
- Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responsesOncoImmunology, 2013
- Osteonecrosis of the Tibia Associated With Imatinib in Metastatic GI Stromal TumorJournal of Clinical Oncology, 2013
- Fulminant course of osteonecrosis of the jaw in a rheumatoid arthritis patient following oral bisphosphonate intake and biologic therapyRheumatology, 2012
- Short time administration of antirheumatic drugs - Methotrexate as a strong inhibitor of osteoblast's proliferation in vitroHead & Face Medicine, 2012
- Osteonecrosis of the jaw related to sunitinibOral and Maxillofacial Surgery, 2010
- Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancerBreast Cancer Research and Treatment, 2010
- Corticosteroid Suppression of VEGF-A in Infantile Hemangioma-Derived Stem CellsThe New England Journal of Medicine, 2010
- Sorafenib-Induced Bilateral Osteonecrosis of Femoral HeadsJournal of Clinical Oncology, 2010
- Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclastsBone, 2004